| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/04/2013 | US8455536 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
| 06/04/2013 | US8455498 Inhibitors of histone deacetylase |
| 06/04/2013 | US8455497 Inhibitors of aspartyl protease |
| 06/04/2013 | US8455464 Dextrin containing compositions for prevention of adhesions |
| 06/04/2013 | US8455443 Methods of use of skin wound healing compositions |
| 06/04/2013 | US8455004 Primary composition comprising a lipophilic bioactive compound |
| 06/04/2013 | CA2542968C Zeolite molecular sieves for the removal of toxins |
| 06/04/2013 | CA2228667C Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers |
| 05/30/2013 | WO2013078261A1 Treatment of muscular conditions and muscular dystrophies |
| 05/30/2013 | WO2013077829A1 Water-soluble pharmaceutical granules |
| 05/30/2013 | WO2013077414A1 Pharmaceutical composition useful for adhesion prevention or hemostasis |
| 05/30/2013 | WO2013077186A1 Activity modulator, medicinal agent comprising same, use of cd300a gene-deficient mouse, and anti-cd300a antibody |
| 05/30/2013 | WO2013076170A1 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis |
| 05/30/2013 | WO2012081982A3 Whey protein composition with a reduced astringency |
| 05/30/2013 | US20130137774 Methods and use of compounds that bind to her2/neu receptor complex |
| 05/30/2013 | US20130137759 Compositions and methods for treating parasitic disease |
| 05/30/2013 | US20130137749 Compositions and Methods for Gene Silencing |
| 05/30/2013 | US20130137743 Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| 05/30/2013 | US20130137741 Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye |
| 05/30/2013 | US20130137740 Combretastatin analogs for use in the treatment of cancer |
| 05/30/2013 | US20130137733 Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses |
| 05/30/2013 | US20130137727 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 05/30/2013 | US20130137711 Polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof |
| 05/30/2013 | US20130137696 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases |
| 05/30/2013 | US20130137686 Benzene, pyridine, and pyridazine derivatives |
| 05/30/2013 | US20130137679 Novel Functionally Selective Ligands of Dopamine D2 Receptors |
| 05/30/2013 | US20130137677 Bicyclic Azaheterocyclic Carboxamides |
| 05/30/2013 | US20130137657 Quaternised ammonium cyclodextrin compounds |
| 05/30/2013 | US20130137648 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| 05/30/2013 | US20130137646 Methods of treatment, pharmaceutical compositions and uses thereof |
| 05/30/2013 | US20130137640 Skin Collagen Enhancing Agent |
| 05/30/2013 | US20130137635 Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease |
| 05/30/2013 | US20130136809 7-hyrdroxyfrullanolide its analogs for prevention control and treatment of metabolic disorders |
| 05/30/2013 | US20130136796 Acellular Bioabsorbable Tissue Regeneration Matrices |
| 05/30/2013 | US20130136791 Multi-phase, mult-compartment capsular delivery apparatus and methods for using same |
| 05/30/2013 | US20130136787 Liposomal Camptothecins and Uses Thereof |
| 05/30/2013 | US20130136782 Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives |
| 05/30/2013 | US20130136771 Oligodeoxynucleotide and its use to induce an immune response |
| 05/30/2013 | US20130136770 Methods for treating respiratory viral infection |
| 05/30/2013 | US20130136756 Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| 05/30/2013 | US20130136740 Methods of treating cancer |
| 05/30/2013 | US20130136737 Uses of NOGO-A Inhibitors and Related Methods |
| 05/30/2013 | US20130136719 Compounds and methods for the treatment or prevention of flavivirus infections |
| 05/30/2013 | US20130136718 Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities |
| 05/30/2013 | US20130136717 Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth |
| 05/30/2013 | US20130136704 P-menthane-3,8-diol isomer mixture, composition comprising the same, and products comprising the mixture or composition |
| 05/30/2013 | US20130136703 Limited release lingual thioctic acid delivery systems |
| 05/30/2013 | US20130136692 Molecular signature of cancer |
| 05/30/2013 | CA2856672A1 Pharmaceutical composition useful for prevention of adhesion or for hemostasis |
| 05/29/2013 | EP2596366A1 Combination therapy with mdm2 and efgr inhibitors |
| 05/29/2013 | EP2596023A2 Compositions and methods featuring il-6 and il-21 antagonists |
| 05/29/2013 | EP2595625A1 Pharmaceutical composition containing a tryptophan derivative |
| 05/29/2013 | EP2595614A1 Composition for retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
| 05/29/2013 | EP2595613A1 Method of preventing or treating viral infection |
| 05/29/2013 | EP2595485A1 Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| 05/29/2013 | EP2595484A1 Methods of use of cyclic amide derivatives to treat schizophrenia |
| 05/29/2013 | CN1525866B Treatment using neublastin polypeptides |
| 05/29/2013 | CN103124563A Combination therapy for the treatment of prostate carcinoma |
| 05/29/2013 | CN103124555A Substrate of three-layer structure and water-containing adhesive patch including same |
| 05/29/2013 | CN103123359A Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease |
| 05/29/2013 | CN103120796A Antitumor compound of dichloroacetic acid connected with alkaline antitumor drug |
| 05/29/2013 | CN103120653A Oral pharmaceutical composition |
| 05/29/2013 | CN102415986B Insoluble medicament solid dispersion containing phosphatide and cholate and preparation method thereof |
| 05/29/2013 | CN102406595B Floating microorganism adhesive porous hydrogel and preparation method thereof |
| 05/29/2013 | CN102370987B Injection liposome entrapping antineoplastic pharmaceutical composition |
| 05/29/2013 | CN101506145B Aminoalcohol derivative and immunosuppressant containing the same as active ingredient |
| 05/28/2013 | US8450377 1-adamantyl chalcones for the treatment of proliferative disorders |
| 05/28/2013 | US8450309 Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| 05/28/2013 | US8450288 For introduction of a disc prosthesis or implant; involves providing substance(s) beneficial to the intervertebral disc through a cannulated element |
| 05/28/2013 | US8449906 Effervescent compositions comprising phosphonates and methods related thereto |
| 05/28/2013 | US8449893 Compositions and dosage regimes comprising a clostridial vaccine and levamisole |
| 05/28/2013 | US8449873 Long-term storage of non-glycosylated recombinant Human G-CSF |
| 05/28/2013 | CA2672716C Novel therapeutic use for treating leukaemia |
| 05/28/2013 | CA2568305C Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues |
| 05/28/2013 | CA2564592C Compositions for improving breast health in women |
| 05/28/2013 | CA2562693C Reverse-turn mimetics and method relating thereto |
| 05/28/2013 | CA2550625C Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 05/28/2013 | CA2521649C Composition and uses of galectin antagonists |
| 05/28/2013 | CA2473970C Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 05/28/2013 | CA2440831C Combination therapy using cd40 and cd20 ligands |
| 05/28/2013 | CA2381468C Percutaneous absorption preparations containing melatonin receptor agonist for percutaneous treatment of sleep disorders |
| 05/28/2013 | CA2323210C Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 05/23/2013 | WO2013074892A1 Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof |
| 05/23/2013 | WO2013074583A1 Treatment and prognosis of lymphangioleiomyomatosis |
| 05/23/2013 | WO2013074320A1 Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| 05/23/2013 | WO2013073667A1 Intestinal fibrosis treatment agent |
| 05/23/2013 | WO2013073454A2 Controlled release composition for physiologically active substance |
| 05/23/2013 | WO2013073382A1 Drug for treatment or prevention of nephropathy |
| 05/23/2013 | WO2013073191A1 Therapeutic agent for early delivery or abortion using plasminogen activator inhibitor-1 |
| 05/23/2013 | WO2013072767A1 Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
| 05/23/2013 | WO2013072392A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
| 05/23/2013 | WO2013042140A3 Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| 05/23/2013 | WO2011119047A8 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia |
| 05/23/2013 | US20130133089 High affinity leptins and leptin antagonists |
| 05/23/2013 | US20130131429 Methods and systems for treating cell proliferation disorders with psoralen derivatives |
| 05/23/2013 | US20130131155 Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates |
| 05/23/2013 | US20130131127 Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
| 05/23/2013 | US20130131123 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 05/23/2013 | US20130131074 Pyridone and pyridazone analogues as gpr119 modulators |
| 05/23/2013 | US20130131068 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof |